The final instalment of In Vivo’s three-part series delves into the therapeutic categories that will propel forecast pharmaceutical sales growth for 2025, focusing on mood disorders, immunodeficiency, viral infections, and blood cell disorders.

But 2024 will see a lull between two strong years.

The next six years will see rapid growth in several newer pharmaceutical technology groups. In this article In Vivo examines the technologies currently forecast to see highest rates of growth, as well as those with the most actual sales growth out to 2030.

The medical industry must scale up to meet rising demand for care with fewer clinicians. Artificial intelligence can take care to the next levels of volume and quality – and in equity of delivery, insists the company, Annalise.ai.

Industry veteran Miguel Forte navigates new kid on the block Kiji Therapeutics into the clinic to prove cell therapy manufacturing doesn’t need to decelerate commercial viability.

Datamonitor Healthcare analysts and podcast co-hosts Flora Mackay and Emma Wille discuss the complicated development of therapeutic psychedelics. They dwell on FDA involvement and advisory committees, alongside adverse event reporting and ethical concerns.

Senior management at the Paris-headquartered drugmaker tell In Vivo about how embracing artificial intelligence has enhanced its ability to accelerate drug discovery, improve clinical trial design and revolutionize its manufacturing and supply processes.

Photonics enhances diagnostic imaging accuracy and speeds up diagnoses, says Antanus Laurutis, CEO of Altechna.

Industry veteran Miguel Forte navigates new kid on the block Kiji Therapeutics into the clinic to prove cell therapy manufacturing doesn’t need to decelerate commercial viability.

Following the pivotal data on Alnylam’s Amvuttra, all eyes turn to the next amyloidosis readout – that of AstraZeneca and Ionis’ Wainua. And the UK major’s ambitions do not stop there.

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

John Lepore, CEO of ProFound Therapeutics and CEO-partner at Flagship Pioneering, discusses the vast possibilities for the human atlas, the benefits of strategic partnering and knowing when to walk away from a project.

After years of heavy price and cost pressures that have taken a toll on firms operating in the US generics market, more recent quarters appear to have reflected a calmer and more predictable landscape. 

As the US struggles to contain the cost of prescription medicines, a growing number of state governments are trying to take matters into their own hands and believe prescription drug affordability boards could be the answer.

Boston Consulting Group and senior pharma industry executives take a broad look at the challenges and opportunities for medical affairs evidence generation with multiple modalities.

Deals in pharma to secure market access are now business as usual. More deals will be needed in future too. Yet they take time and are not easy to successfully conclude. Could nudging the negotiations help?

Datamonitor Healthcare analysts and podcast co-hosts Flora Mackay and Emma Wille discuss the complicated development of therapeutic psychedelics. They dwell on FDA involvement and advisory committees, alongside adverse event reporting and ethical concerns.

An interactive look at pharma, medtech and diagnostics deals made during August 2024. Data courtesy of Biomedtracker.

After years of heavy price and cost pressures that have taken a toll on firms operating in the US generics market, more recent quarters appear to have reflected a calmer and more predictable landscape. 

Six $1bn+ alliances were penned in August. In the top alliance by deal value, ImmuneOnco Biopharmaceuticals licensed Instil Bio global rights (excluding China, Taiwan, Macau, and Hong Kong) to develop and commercialize its PD-L1xVEGF bispecific antibody IMM2510 and the next-generation anti-CTLA-4 antibody IMM27M. The deal could be worth over $2bn. The candidates have potential in treating advanced solid tumors.

Following the pivotal data on Alnylam’s Amvuttra, all eyes turn to the next amyloidosis readout – that of AstraZeneca and Ionis’ Wainua. And the UK major’s ambitions do not stop there.

An interactive look at pharma, medtech and diagnostics deals made during August 2024. Data courtesy of Biomedtracker.

After years of heavy price and cost pressures that have taken a toll on firms operating in the US generics market, more recent quarters appear to have reflected a calmer and more predictable landscape. 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Senior management at the Paris-headquartered drugmaker tell In Vivo about how embracing artificial intelligence has enhanced its ability to accelerate drug discovery, improve clinical trial design and revolutionize its manufacturing and supply processes.

Photonics enhances diagnostic imaging accuracy and speeds up diagnoses, says Antanus Laurutis, CEO of Altechna.

Can the new UK government's raw enthusiasm for NHS reform be a catalyst for real change where countless past attempts to address the national provider's shortcomings have failed to hit the spot? And what might the 10-year plan mean for medtech?

Six $1bn+ alliances were penned in August. In the top alliance by deal value, ImmuneOnco Biopharmaceuticals licensed Instil Bio global rights (excluding China, Taiwan, Macau, and Hong Kong) to develop and commercialize its PD-L1xVEGF bispecific antibody IMM2510 and the next-generation anti-CTLA-4 antibody IMM27M. The deal could be worth over $2bn. The candidates have potential in treating advanced solid tumors.

The final instalment of In Vivo’s three-part series delves into the therapeutic categories that will propel forecast pharmaceutical sales growth for 2025, focusing on mood disorders, immunodeficiency, viral infections, and blood cell disorders.

But 2024 will see a lull between two strong years.

Updated guidance on the risk of cardiotoxicity in patients following cancer treatment is expected soon. The first consensus guidelines were issued eight years ago. AI is being used for early risk identification, Philips said during the European Society of Cardiology congress 2024.